Abstract
Enzymatic transformation of then-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA) by the 5-lipoxygenase (LO) enzyme results in the formation of leukotrienes (LTs) including leukotriene B4 (LTB4), which is a potent mediator of inflammation. The purpose of the present study was to determine the effect of othern-6 fatty acids on the formation of LTB4 by human neutrophils and to determine if thesen-6 fatty acids themselves may be transformed into products with antiinflammatory capacity. Purified neutrophils isolated from heparinized human venous blood were incubated with A23187 (5 μM) and different concentrations (0–100 μM) of then-6 fatty acids linoleic acid (LA) and dihomo-gammalinolenic acid (DGLA). LO products were determined by use of quantitative reversed-phase high performance liquid chromatography (RP-HPLC) and mass spectrometry. The formation of LTB4 was dose dependently inhibited by both LA (IC50=45 μM) and DGLA (IC50=40μM). This inhibition of LTB4 formation was associated with a dose dependent increase in the formation of the respective 15-LO products of LA (13-hydroxy-octadecadienoic acid; 13-HODE) and DGLA (15-hydroxy-eicosatrienoic acid; 15-HETrE). To determine whether these 15-LO products themselves might inhibit LTB4 formation, neutrophils were incubated with 13-HODE and 15-HETrE. Both 15-LO products lead to a dose-dependent inhibition of LTB4 formation (IC50=7.5 μM and IC50=0.2 μM). For comparison the 15-LO product of AA, 15-hydroxy-eicosatetraenoic acid (15-HETE), also inhibited LTB4 formation (IC50=0.75 μM). The results show that the addition of LA and DGLA to neutrophils results in an inhibition of LTB4 formation and simultaneously to the formation of 13-HODE and 15-HETrE, that also inhibits LTB4 formation. Therefore, dietary supplementation or topical application of LA and DGLA or preferentially their respective 15-LO products, may have a therapeutic effect in inflammatroy diseases in which LTs are suspected to play a pathogenic role.
Article PDF
Similar content being viewed by others
References
V. A. Ziboh and R. S. Chapkin,Metabolism and function of skin lipids. Prog. Lipid. Res.27, 81–105 (1988).
W. F. Stenson and C. W. Parker,Metabolites of arachidonic acid. Clin. Rev. Allergy1, 369–384 (1983).
B. Samuelsson,Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science220, 568–575 (1983).
R. D. R. Camp, R. R. Jones, S. Brain, P. Woollard and M. Greaves,Production of intraepidermal microabscesses by topical application of leukotriene B 4. J. Invest. Dermatol.82, 202–204 (1984).
N. A. Soter, R. A. Lewis, E. J. Corey and K. F. Austen,Local effects of leukotrienes (LTC 4, LTD4, LTE4, and LTB4)in human skin. J. Invest. Dermatol.80, 115–119 (1983).
C. B. Archer, C. P. Page, L. Juhlin, J. Morley and D. MacDonald,Delayed-onset synergism between leukotriene B 4 and prostaglandin E 2 in human skin. Prostaglandins33, 799–805 (1987).
F. W. Bauer, P. C. M. van de Kerkhof and R. M. Maassen De Grood,Epidermal hyperproliferation following the induction of microabscesses by leukotriene B 4. Br. J. Dermatol.114, 409–412 (1986).
S. Brain, R. Camp, P. Dowd, A. K. Black and M. Greaves,The release of leukotriene B 4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J. Invest. Dermatol.83, 70–73 (1984).
K. Fogh, T. Herlin and K. Kragballe,Eicosanoids in acute and chronic psoriatic lesions. Leukotriene B 4,but not 12-hydroxy-eicosatetraenoic acid is present in biologically active concentrations in acute guttate lesions. J. Invest. Dermatol.92, 837–841 (1989).
T. Ruzicka, T. Simmet, B. A. Peskar and J. Ring,Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J. Invest. Dermatol.86, 105–108 (1986).
K. Fogh, T. Herlin and K. Kragballe,Eicosanoids in skin of patients with atopic dermatitis. Prostaglandin E 2 and leukotriene B 4 are present in biologically active concentrations. J. Allergy Clin. Immunol.43, 450–455 (1989).
J. Y. Vanderhoek, R. W. Bryant and J. M. Bailey,Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J. Biol. Chem.255, 10064–10066 (1980).
J. Y. Vanderhoek, R. W. Bryant and J. M. Bailey,Regulation of leukocyte and platelet lipoxygenases by hydroxyeicosanoids. Biochem. Pharmacol.31, 3463–3467 (1982).
K. Fogh, E. S. Hansen, T. Herlin, V. Knudsen, T. B. Henriksen, H. Ewald, C. Bünger and K. Kragballe,15-Hydroxy-eicosatetraenoic acid (15-HETE) inhibits carragheenan-induced experimental arthritis and reduces synovial fluid leukotriene B 4 (LTB 4). Prostaglandins37, 213–228 (1989).
C. R. Lovell, J. L. Burton and J. F. Horrobin,Treatment of atopic eczema with evening primrose oil Lanceti, 278 (1982).
A. Bjørneboe, A. K. Smith, G.-E. Bjørneboe, P. O. Thune and C. A. Drevon,Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of psoriasis. Br. J. Dermatol.118, 77–83 (1988).
V. A. Ziboh, K. A. Cohen, C. N. Ellis, C. Miller, T. A. Hamilton, K. Kragballe, C. R. Hydrick and J. J. Voorhees,Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Arch. Dermatol.122, 1277–1282 (1986).
K. Kragballe and K. Fogh,A low-fat diet supplemented with dietary fish oil (Max-EPA) results in improvement of psoriasis and in formation of leukotriene B 5. Acta Derm. Venereol.69, 23–28 (1989).
K. Fogh, K. Kragballe, E. Larsen, H. Egsgaard and V. K. S. Shukla,Mass spectrometry of underivatized 15-hydroxyeicosatetraenoic acid and 15-hydroxyeicosapentaenoic acid. Biomed. Environ. Mass. Spectrom.17, 459–461 (1988).
K. Fogh, T. Herlin and K. Kragballe,In vitro inhibition of leukotriene B 4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxyeicosatetraenoic acid (15-HETE) by human neutrophils. Arch. Dermatol. Res.280, 430–436 (1988).
I. Ahnfelt-Rønne and U. B. Olsen,Leukotriene production in rat peritoneal leukocytes requires intact energy metabolism. Biochem Pharmacol.34, 3095–3100 (1985).
M. Peters-Golden and C. Shelly,Inhibitory effect of exogenous arachidonic acid on alveolar macrophage 5-lipoxygenase metabolism. Role of ATP depletion. J. Immunol.140, 1958–1966 (1988).
B. A. Burrall, M. K. L. Cheung and E. J. Goetzl,Inhibition of the 15-lipoxygenase of human neonatal foreskin keratinocytes by adenosine 5′-triphosphate. Clin. Res.35, 387A (1987) (Abstract).
R. D. R. Camp and N. J. Fincham,Inhibition of ionophore stimulated leukotriene B 4 production in human leucocytes by monohydroxy fatty acids. Br. J. Pharmac.85, 837–841 (1985).
C. C. Miller, C. A. McCreedy, A. D. Jones and V. A. Ziboh,Oxidative metabolism of dihomogammalinolenic acid by guinea pig epidermis, evidence of generation of anti-inflammatory products. Prostaglandins35, 917–938 (1988).
P. Borgeat, B. F. de Laclos and J. Maclouf,New concepts in the modulation of leukotriene synthesis. Biochem. Pharmacol.32, 381–387 (1983).
D. Wilkinson, C. Hallam, P. E. Hamsley, G. H. Lord and P. D. Mitchell,15-L(S)-hydroxy-5z-8z,11z,13e-eicosatetraenoic acid is a substrate for 5-lipoxygenase. Biochem. Soc. Trans.13, 180–182 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iversen, L., Fogh, K., Bojesen, G. et al. Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophilsin vitro. Evidence of formation of antiinflammatory compounds. Agents and Actions 33, 286–291 (1991). https://doi.org/10.1007/BF01986575
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01986575